356
Participants
Start Date
July 31, 2002
Primary Completion Date
May 31, 2003
Study Completion Date
May 31, 2003
Lurasidone 20 mg
Lurasidone 20mg/day tablets
Lurasidone 40mg
Lurasidone 40mg/day tablets
Lurasidone 80 mg
Lurasidone 80mg/day - 2 40mg tablets
Haloperidol 10mg
Haloperidol 10mg/day tablets
Placebo
Matching Placebo to Lurasdione and Haloperidol
Quantum Clinical Services Group, Philadelphia
Albert Einstein Medical Center - Dept. of Psychiatry, Philadelphia
Comprehensive Neuroscience. Inc., Washington D.C.
Centers for Behavioral Health, LLC, Rockville
CNS, Inc., Falls Church
Carman Research, Smyrna
Atlanta Center for Medical Research, Atlanta
Coordinated Research of Florida, Inc., Winter Park
Comprehensive Neuroscience. Inc., Melbourne
Segal Institute for Clinical Research, North Miami
University of South Florida, Tampa
Birmingham Psychiatry Pharmaceutical, Birmingham
Psychiatric Professional Services Inc, Cincinnati
Medstream, Inc., Milwaukee
Alexian Brothers Behavioral Health Hospital, Hoffman Estates
American Medical Research, Oak Brook
St. Paul Medical Center, Dallas
University Hills Clinical Research, Dallas
Claghorn Lesem Research Clinic, Inc., Bellaire
Community Clinical Research, Austin
FutureSearch Trials, Austin
Lake Mead Hospital, North Las Vegas
Institute for Psychopharmacology Research, Cerritos
California Clinical Trials Medical Group, Glendale
Optimum Health Services, La Mesa
Affiliated Research Institute, San Diego
Sharp Mesa Vista Hospital, San Diego
California Neuropsychopharmacolgoy Clinical Research Insitute, San Diego
CNS Network, Garden Grove
University of California, Irvine, Orange
Hawaii Research Center, Honolulu
Northwest Clinical Research Center, Belleview
Comprehensive Clinical Research CNS, PC, Clementon
ClinSearch, Inc., Kenilworth
Sumitomo Pharma America, Inc.
INDUSTRY